Fig. 2

SOX11 promotes oral/head and neck cancer cell proliferation and chemoresistance. (a) Western blotting confirmation of SOX11 expression in Sox11-silencing UM1 cells and Sox11-overexpression UM2 cells. (b) MTS assays of stable Sox11-knockdown UM1 cells (sh-Sox11–1 and sh-Sox11–2) and Sox11-overexpression UM2 cells (Sox11–1 and Sox11–2). **, P < 0.01 compared with control cells. (c) Cell survival was examined in Sox11 knockdown (UM1) and overexpression (UM2) cancer cells after treatment with the indicated doses of Cisplatin (0, 2.5, 5, 10, 20 or 40 μM). (d) Colony formation rate in Sox11 knockdown (UM1) and overexpression (UM2) cancer cells. *, P < 0.05 compared with control cells. (e) Tunel staining of Sox11 knockdown cells. ***, P < 0.01 compared with control cells. (f) Knockdown of Sox11 suppresses xenograft tumor growth in vivo. Stable Sox11 knockdown UM1 cells were subcutaneously injected into nude mice. Four weeks later, Sox11 knockdown UM1 cells had smaller tumors than controls (***, P < 0.001). Western blot analysis indicated decreased expression of SOX11 in xenograft tumors derived from UM1 cells with stable Sox11 knockdown